News
$Syros Pharmaceuticals (SYRS.US)$ Reuters· 1 min ago1min
Syros Announces Topline Data From Select-Mds-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome With Rara Gene Overexpression! Did not meet endpoint!
Syros Announces Topline Data From Select-Mds-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome With Rara Gene Overexpression! Did not meet endpoint!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
